The pharmacokinetics of ibuprofen suspension, chewable tablets, and tablets in children with cystic fibrosis

Journal of Pediatrics

Volumn 134, Issue 1, 1999, Pages 58-63

  Scott, Christy S ^a,b   Retsch Bogart, George Z ^a   Kustra, Robert P ^a   Graham, Katie M ^a   Glassock, Bradley J ^a   Smith, Philip C ^a  

^a Department of Pediatrics   (United States)

^b University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBUPROFEN; MOTRIN CHEWABLE; UNCLASSIFIED DRUG;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHEWABLE TABLET; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUSPENSION; TABLET;

EID: 0032942054     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(99)70387-2     Document Type: Article

References (22)

1. 1. Auerbach HS, Williams M, Kirkpatrick JA, Colen HR. Alternative-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985;2:686-8.
2. 2. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV. A multi-center study of alternate-day prednisone in patients with cystic fibrosis. J Pediatr 1995;126:515-23.
3. 3. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:848-54.
4. 4. Birrer P, McElvaney NG, Rudeberg A, Wirz Sommer C, Liechti-Gallati S, Kraemer R, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Resp Crit Care Med 1994;150:207-13.
5. 5. Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995;310: 1571-2.
6. 6. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DWH. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-82.
7. 7. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Gutierrez JP, Hull J, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997;156:1197-204.
8. 8. Noah TL, Black HR, Cheng P, Wood RE, Leigh MW. Nasal and bronchoalveolar lavage fluid cytokmes in early cystic fibrosis. J Infect Dis 1997;175:638-47.
9. 9. Konstan MW, Hoppel CL, Chai B, Davis PB. Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. J Pediatr 1991;118: 956-64.
10. 10. Rifai N, Sakamoto M, Law T, Galpchian V, Harris N, Cohn A. Use of a rapid HPLC assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis. Clin Chem 1996;42:1812-6.
11. 11. Castillo M, Smith PC. Direct determination of ibuprofen and ibuprofen acyl glucuronide in plasma by high-performance liquid chromatography using solid-phase extraction. J Chromatography 1993;614;109-16.
12. 12. Rifai N. Personal communication. March 1998.
13. 13. Gibaldi M. Gastrointestinal absorption: role of the dosage form. Biopharmaceutics and pharmacokinetics. 4th ed. Philadelphia: Lea and Febiger; 1991. p. 61-79.
14. 14. Questions and answers - ibuprolen: information for cystic fibrosis physicians. Bethesda (MD): Cystic Fibrosis Foundation. March 30, 1995.
15. 15. Konstan MW, Vargo KM, Davis PB. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Am J Respir Crit Care Med 1990;141:186-92.
16. 16. Boreus LO. Principles of pediatric clinical pharmacology. New York: Churchill Lvingstone; 1982.
17. 17. Milsap RL, Hill MR, Szefler SJ. Special pharmacokinetic considerations in children. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver (WA): Applied Therapeutics, Inc; 1986.
18. 18. Kauffman RE, Nelson MV. Effect of age on ibuprofen pharmacokinetics and antipyretic response. J Pediatr 1992;121:969-73.
19. 19. Malfroot A, Dab I. New insights on gastro-oesophageal reflux in cystic fibrosis by longitudinal follow up. Arch Dis Child 1991;66:1339-45.
20. 20. Cucchiara S, Raia V, Minella R, Frezza T, De Vizia B, De Ritis. Ultrasound measurement of gastric emptying time in cystic fibrosis and effect of ranitidine on delayed gastric empyting. J Pediatr 1996;128:485-8.
21. 21. McEvoy G (editor). AHFS Drug Information 97. Bethesda (MD): American Society of Health-System Pharmacists, Inc; 1997.
22. 22. Welling PG. Interactions affecting drug absorption. Clin Pharmacokinet 1984;9:404-34.